



# **Syntázy oxidu dusnatého (NO synthases - NOSs)**

# Oxid dusnatý (NO)



- Zloženie: atóm kyslíku a dusíku viazané dvojnou väzbou
- Atom kyslíku nesie 2 páry (nevazebných) elektrónov
- Atom dusíku má 1 pár nevazebných elektrónov a jeden nepárový elektrón





- V savčích buňkách je NO tvoren oxidáci terminálneho guanidino dusíku L-arginínu molekulárnym kyslíkom; kromě NO vzniká L-citrulín.
- Celou komplexní reakci katalyzuje jediný enzym, NO syntáza, ktorá existuje 3 isoformách.



# Furchgottův sandwich

Furchgott prokázal, že relaxace cév indukovaná acetylcholinem je závislá na endoteliu. Použil dva kousky aorty, u jednoho odstranil epitelium



**Robert F Furchgott**

1916



Dept. of Pharmacology,  
SUNY Health Science Center  
New York

## Ignarrova spektrální analýza

Ignarro pomocí spektrální analýzy prokázal, že EDRF je totožný s NO.

Hemoglobin (žlutý) exponovaný endoteliálním buňkám produkujícím EDRF (konverze oxyhemoglobinu na methemoglobin).

Hemoglobin (žlutý) exponovaný přímo NO.  
Posun v absorbní křivce je identický (EDRF = NO).



**Louis J Ignarro,**  
1941


Dept. of Molecular and  
Medical Pharmacology  
UCLA School of  
Medicine  
Los Angeles

## Muradova enzymatická aktivace

Murad věděl, že nitroglycerin působí relaxaci hladké svaloviny.

Enzym guanylát cyklasa byla aktivována a indukovala zvýšení cGMP s následnou relaxací svalu.


Působí nitroglycerin cestou uvolňování NO ???  
Probublával NO přes tkáň obsahující enzym – cGMP se zvyšoval.



**Ferid Murad**

1936

Dept. of Integrative Biology  
Pharmacology and  
Physiology  
University of Texas Medical  
School, Houston




## Něco málo chemie o NO

NO je radikál (lichý počet valenčních elektronů, konkrétně 11 - o 1 víc než  $N_2$ , o 1 míň než  $O_2$ )  
to, že je to radikál, se někdy zdůrazňuje tečkou ( $\dot{N}O$ ), to ale není nutné, "radikálovost" je implicitní v označení NO

z  $N_2$  a  $O_2$  se tvoří jen za specifických podmínek při vysokých teplotách, např. při blesku; taky vzniká ve spalovacích motorech a tepelných elektrárnách

samovolně se nerozkládá, jen za vyššího tlaku - při něm povolna vzniká 2-3 % toxického  $NO_2$  za měsíc (pozor na skladování v bombách!)

poměrně málo rozpustný ve vodě ( $\sim 1.7$  mmol/l při  $25^\circ C$ ), t.j. řádově podobně jako  $O_2$  či  $N_2$



v přítomnosti kyslíku podléhá **autooxidaci** za vzniku  $\text{NO}_2$ :  $2 \text{NO} + \text{O}_2 \rightarrow 2 \text{NO}_2$   
autooxidace je asi 200x rychlejší v roztoku než v plynné fázi  
autooxidace je rychlá (několik sec), je-li NO i  $\text{O}_2$  hodně, ale celkem pomalá, je-li NO málo - jako je tomu většinou v tkáních, kde je NO méně než  $10 \mu\text{M}$  (poločas NO tam může být až 500 sec)

ve vodném roztoku jsou produktem autooxidace nitrity ( $\text{NO}_2^-$ ), pouze v přítomnosti hemoproteinů proběhne oxidace až na nitráty ( $\text{NO}_3^-$ )

v přítomnosti **superoxidu** vzniká extrémně rychle **peroxynitrit**:



$\text{}^-\text{OONO}$  není radikál, ale je velmi reaktivní a cytotoxický


NO je velmi rychle **inaktivován** oxidací s železem **oxyhemoglobinu** za vzniku  $\text{NO}_3^-$

---


---

# FYZIOLOGIE NO

---



- Neurotransmitter - učer
- Zabíjí viry, bakterie, par
- (kortokosteroidy)
- Inhibuje mitochondriáln
- Vazodilatace závislá na
- Nejvíc NO se dělá v no



**Příklad:** koncentrace NO ve vydechovaném vzduchu zdravých lidí. Hodnoty jsou nejvyšší při odebrání vzorku z nosu a postupně nižší v ústech a dále v úsecích dýchacích cest. V periferní průdušce je koncentrace NO pod detekčním limitem vysoce citlivé chemiluminiscenční metody (*Chest 110: 930-938; 1996*).

Pravděpodobně důležit




Za fyziologických podmienok sa oxid dusnatý tvorí v organizme v nízkych koncentráciách (pM). Je rozpustný vo vode a v lipidoch, a preto veľmi rýchlo a ochotne difunduje cez cytoplazmatické aj plazmatické membrány. V takomto prípade prevláda jeho regulačné pôsobenie:

**cGMP-dependentné účinky** – NO aktivuje enzým guanylát cyklázu, čím sa zvyšuje koncentrácia cyklického guanozín-3',5'-monofosfátu (cGMP) v cieľových bunkách. cGMP potom priamo reguluje mnohé bunkové funkcie. Riadi niektoré bunkové kanály, znižuje intracelulárnu koncentráciu  $Ca^{2+}$  iónov a inhibuje kontraktálny aparát v hladkom svalstve. Okrem toho reguluje vāzodilatáciu ciev, moduluje srdcovú kontraktilitu a znižuje zrážanlivosť krvi. Nemenej dôležitý je jeho funkčný podiel na neurotransmisii a tvorbe pamäťovej stopy.

**cGMP-indepedentné účinky** - V tomto prípade sa oxid dusnatý uplatňuje pri inhibícii syntézy DNA a aj celkového energetického metabolizmu bunky. Reguluje metabolizmus železa.

Pri zápalových procesoch sa jeho koncentrácia v organizme mnohonásobne zvyšuje (μM). Vtedy sa NO a aj jeho reaktívne metabolity účastnia na protizápalových, antibakteriálnych, antivirálnych a antioxidačných procesoch. Cytotoxické a cytostatické účinky oxidu dusnatého sprostredkovávajú bunky imunitného systému, zúčastňujúce sa zápalových procesov. Sú to neutrofily, monocyty a makrofágy.



# Syntázy oxidu dusnatého

- **neuronální** syntáza oxidu dusnatého (NOS1 = nNOS)
- **inducibilní** syntáza oxidu dusnatého (NOS2 = iNOS)
- **endotheliální** syntáza oxidu dusnatého (NOS3 = eNOS)


## Každá z těchto syntáz:

- má rozdílnou tkáňovou distribuci
- lokalizovaná na různých chromozomech

Name	Present in	Stimuli	Description
<b>Neuronal NOS</b> (nNOS or NOS1)	Central and peripheral neurons, platelets, pancreatic $\beta$ cells, epithelial cells	NMDA, insulin, thrombin	Produces NO in neuronal tissue in both the central and peripheral nervous system. Neuronal NOS also performs a role in cell communication and is associated with plasma membranes. nNOS action can be inhibited by NPA (N-propyl-L-arginine).
<b>Inducible NOS</b> (iNOS or NOS2)	Macrophages, endothelial cells, chondrocytes, hepatocytes, smooth muscle cells	Endotoxin, IFN- $\gamma$ , IL-1, TNF- $\alpha$	Can be found in the immune system but is also found in the cardiovascular system. It uses the oxidative stress of NO (a free radical) to be used by macrophages in immune defence against pathogens.
<b>Endothelial NOS</b> (eNOS or NOS3 or constitutive/ cNOS)	Endothelial cells, neurons, cardiac myocytes	Acetylcholine, ADP, thrombin, shear stress, VEGF	Generates NO in blood vessels and is involved with regulating vascular function. A constitutive $Ca^{2+}$ dependent NOS provides a basal release of NO. eNOS is associated with plasma membranes surrounding cells and the membranes of Golgi bodies within cells.

# Všetky 3 isoformy NO syntázy

- Sú aktívne jako homodiméry
- Obsahujú v aktívnom centre hem
- Sú stereošpecifické (D-arginín nie je substrátom)
- Jako kofaktory vyžadujú:
  - NADPH
  - 6(R)-5,6,7,8-tetrahydrobiopterin (BH<sub>4</sub>)
  - FAD FMN
  - kalmodulin (ten sa k NOS typu I a III váže po navázaní Ca na kalmodulin, NOS II váže kalmodulin trvale)



Electrons (e<sup>-</sup>) are donated by NADPH to the reductase domain of the enzyme and proceed via FAD and FMN redox carriers to the oxygenase domain. There they interact with the heme iron and BH<sub>4</sub> at the active site to catalyse the reaction of oxygen with L-Arginine, generating citrulline and NO as products. Electron flow through the reductase domain requires the presence of bound Ca<sup>2+</sup>/CaM.

**Flavin adenine dinucleotide (FAD)** is the precursor molecule to FADH<sub>2</sub>. Upon binding to two hydrogen atoms, FAD is then changed to FADH<sub>2</sub> and is turned into an **energy-carrying molecule**. FAD is a **coenzyme** derived from **riboflavin**, or vitamin B<sub>2</sub>. Many **oxidoreductases**, called **flavoenzymes** or **flavoproteins**, require FAD as a prosthetic group which functions in electron transfers.

**Flavin mononucleotide (FMN)**, or **riboflavin-5'-phosphate**, is also derived from **riboflavin** (vitamin B<sub>2</sub>) and serves as a **cofactor** of various **oxidoreductases** including **NADH dehydrogenase**.


## Neuronal Nitric Oxide Synthase (nNOS, Type I)

Homodimers with 2 subunits (130-160 kDa)

nNOS have binding sites for NADPH, FAD, and FMN near the carboxyl terminus (the reductase domain), and binding sites for tetrahydrobiopterin (BH<sub>4</sub>) and heme near the amino terminus (the oxygenase domain). The reductase and oxygenase domains are linked by a calmodulin (CaM) binding site. Occupation of this site facilitates electron transfer from the cofactors in the reductase domain to heme during nitric oxide production.

nNOS is associated with the post-synaptic density protein (PSD-95) in the neuronal membrane. In response to increased intracellular Ca<sup>●+</sup>, nNOS interacts with CaM. The Ca<sup>2+</sup>-CaM complex, in combination with BH<sub>4</sub>, binds to nNOS and induces its translocation from the plasma membrane to the cytoplasm.






---



---



---



---



---




---



---



---




The dephosphorylation of nNOS by calcineurin initiates the production NO. NO activates guanylyl cyclase (GC) and activates the various cGMP-regulated signaling pathways. nNOS is inactivated by phosphorylation by protein kinase A (PKA) or protein kinase C (PKC).

Neuronal nitric oxide synthase (nNOS) has been implicated in a wide variety of physiological and pathological processes. These include neurotransmission, neurotoxicity, skeletal muscle contraction, sexual function, body fluid homeostasis and atherosclerosis, among others.

# Endothelial nitric oxide synthase (eNOS or NOS3 or constitutive/ cNOS)

- localised to caveolae
- eNOS is a lipid raft/caveolar protein apparently regulated by caveolin
- Agonist stimulation induces calcium dependent association of protein cofactors and kinases ultimately resulting in generation of nitric oxide from Arginine



## Caveolae

- small invaginations (vesicles) of the plasma membrane with a well-defined size (50-100 nm) and a particular lipid content
- localised in plasma membrane (lipid rafts-rich in glycosphingolipids and cholesterol)
- Involved in transcytosis, lipid trafficking and more recently signal transduction
- very dynamic organelles that can pinch off the plasma membrane in a process that requires the hydrolysis of GTP
- mediate trans-epithelial transport of small molecules across the cell by fusing together to form trans-cellular channels
- mediate the uptake of particular molecules and ions from the exterior and then redistribute these compounds in intracellular compartment through a process called potocytosis
- cycle between the plasma membrane and the ER for delivery of molecules inside the cell
- many receptors and cytosolic signaling proteins that do not require lipid modifications to associate with membranes, such as PKC $\alpha$ , are reportedly found in caveolae
- number of viruses, parasites and bacteria utilize caveolae (or caveolae-like domains) as an alternative route to enter cells.

### Proteins called caveolins



- represent major components of the caveolar coat
- important for the structure of caveolae, thanks to their ability to oligomerize and bind cholesterol
- caveolin-1 and 2 have a similar tissue distribution, being mainly expressed in endothelial, epithelial and muscle cells
- caveolin-3 expression is limited to muscle cells

caveolin-1 adaptor molecule or scaffolding protein in signal transduction Caveolin-1 functions as a tumor suppressor in human colon carcinoma cells


Bender et al., Biol Res 35 (2002) 139-150, Caveolae and caveolae-like membrane domains in cellular signaling and disease: Identification of downstream targets for the tumor suppressor protein caveolin-1

## Lipid rafts

- In artificial membranes, different lipids separate from each other based on their physical properties, forming small islands called lipid rafts. These rafts have a higher concentration of certain specialized lipids, called glycosphingolipids, and cholesterol than do non-raft parts of the membrane. Rafts are also distinguished by a different assortment of proteins. Certain types of proteins cluster together in rafts, while others remain mostly outside of rafts.
- Although the existence of lipid rafts in cellular membranes remains controversial, many scientists believe they serve as communication hubs by recruiting proteins that need to come together in order to transmit a signal. They are important signal transduction centers in the plasma membrane, coordinating and integrating incoming signals, especially in tyrosine kinase signalling. Researchers are beginning to link lipid rafts with a variety of diseases, including AIDS, Alzheimer's, anthrax, and atherosclerosis.



<http://www.scielo.cl/fbpe/img/bres/v35n2/img06-01.gif>



[http://www.steve.gb.com/images/science/lipid\\_raft.png](http://www.steve.gb.com/images/science/lipid_raft.png)



# Regulation of Endothelial Nitric Oxide Synthase

## Classical regulation by calcium

All NO-synthases required for its activation to be bound to a calcium regulatory protein: **calmodulin**.

iNOS tightly binds calmodulin even at resting calcium concentrations, and then it is active once it is synthesized.

Constitutive enzymes, eNOS and nNOS, only bind calmodulin when the intracellular calcium concentration increase up to a certain value. Agents that increase intracellular calcium concentration, either by allowing calcium entrance from the outside or by stimulating calcium mobilization from intracellular stores, can activate these constitutive enzymes.

In endothelial cells various substances increase intracellular calcium and in consequence NO synthesis: **bradykinin, histamine, serotonin**.



Calcium-independent regulation

Activity of eNOS is acutely dependent on intracellular localization and also dependent on phosphorylation at specific aminoacids.

Intracellular localization


- eNOS is predominantly localized in caveolae (specialized invaginations of the plasma membrane), where it is closely regulated by interaction with caveolin-1. Modifications preventing membrane localization of eNOS also result in the absence of NO synthetic activity in the intact cells. Membrane distribution is probably needed by the presence in the same localization of other proteins important for eNOS activity: the cationic amino acid transporter CAT-1 (involved in the uptake of L-arginine, substrate for NO synthesis), calcium pump and the bradykinin receptor are also present in caveolae.
- Although membrane distribution is an essential requirement for eNOS activity, at plasma membrane the enzyme activity is closely regulated by caveolin-1. This intrinsic protein strongly reduces eNOS activity by interfering with calmodulin binding. Intracellular calcium increase or shear stress displace caveolin-1 and allow eNOS activation.
- Membrane localization of eNOS is modulated by certain post-translational modifications:
  - Myristoylation distinguish eNOS from nNOS and iNOS, that are predominantly cytosolic proteins
  - Palmitoylation is also required for a proper localization of eNOS in the membrane

Phosphorylation: Tyr-Phosphorylation, Ser/Thr-Phosphorylation

Oxygen free radicals

- In addition to direct regulation of NO-synthases, NO availability is also dependent on the quantity of oxygen free radicals generated by cells surrounding NO-producer cell. In fact, eNOS may generate superoxide instead of NO in certain conditions (e.g. low L-arginine levels). Whatever the origin of superoxide (eNOS, xanthine oxidase,...) this compound rapidly reacts with NO to form peroxynitrite. In certain pathological circumstances an increase in superoxide formation can be determinant in reducing NO availability.

[Based on Govers and Rabelink, Am J Physiol 2001, 280:F193]



# Regulation of eNOS

**factors that regulate the transcription** of eNOS gene (shear stress, estrogen and hypoxia)

**factors that modulate the stability of its mRNA** (tumor necrosis factor alfa or TNF-alfa, lipopolysacharide or LPS, and vascular endothelial group factor or VEGF)

**permanent changes of the eNOS protein e.g. myristoylation, palmitoylation,** myristoylation seems a critical factor to allow the final location of the enzyme at certain specific domains of the membrane.

**non-permanent changes of eNOS protein e.g. phosphorylation and specific interactions with another proteins.** After those modifications the eNOS protein is active and synthetizes NO or in some cases superoxide ion (this later circunstance can take place when the substrate, L-arginine, or tetrahydrobiopterin are deficient and has pathophysiological consequences). Then, all these non-permanent modifications of eNOS revert and eNOS is deactivated. A cycle of activation-deactivation occurs in parallel with a cycle of association and dissociation from the caveoale at the plasma membrane. [Based on Govers and Rabelink, Am J Physiol 2001, 280:F193]





eNOS gene

transcription

+ shear stress  
estrogen  
- hypoxia

Degradated mRNA


+ TNF- $\alpha$ , LPS

- VEGF




eNOS mRNA

translation




eNOS protein

myristoylation




myristoyl-eNOS

palmitoylation




palmitoyl-eNOS

Protein protein interaction



eNOS + other proteins

phosphorylation



**ACTIVE phosphorylated-eNOS**

# Inducible nitric oxide synthase (iNOS, NOS II)

generates NO independently of intracellular calcium concentrations induced by immunostimulatory cytokines, bacterial products or infection in a number of cells e.g. endothelium, hepatocytes, monocytes, mast cells, macrophages and smooth muscle cells (function in host defense against microbial and viral pathogens)

responsible for formation of NO radicals or S-nitrosothiols or ONOO<sup>-</sup> in the host cell or in the microbe itself

participate in the pathology of inflammatory diseases including atherosclerosis, rheumatoid arthritis, diabetes, septic shock, transplant rejection, and multiple sclerosis, leading to cell death (F. Aktan, Life Sciences 75 (2004) 639–653)



# Indukcia a regulácia iNOS expresie

Indukcia iNOS:

nešpecifická (oxidatívny stres, UV-žiarenie)

Pomocou špecifických receptorov (ligandy TNF- $\alpha$ , IL-1, CD-40L, LPS)

Regulácia iNOS sa uskutočňuje na **BUNEČNEJ** a **MOLEKULÁRNEJ** úrovni

Kľúčovým faktor pre syntézu NO je zvýšenie expresie génu pre iNOS a regulácia transkripcie tohoto génu (väzobné miesta pre transkripčné faktory, ktoré sa nachádzajú na iNOS promótoře)


→ Miesta určené pre špecifické transkripčné faktory: jadrové faktory-kappaB (**NF- $\kappa$ B**), aktivačný proteín-1 (**AP-1**), CCAAT/enhancer-binding protein **C/EBP** a cyklický-AMP-responzívny element viažúci proteín (**CREB**)

Makrofágy (tkanivová forma monocytov) - veľmi dôležitú úlohu v zápalových procesoch (LPS, IFN- $\gamma$ , TNF... ). Odpoveď na stimuláciu → produkcia prozápalových mediátorov (IL-1, IL-2, TNF- $\alpha$ , NO...)



## Regulation of iNOS induction at the molecular level.

Transcription factors controlling induction of the iNOS gene. Activated STAT1 induces transcription of the IRF-1 and iNOS genes, an effect which is competed by activated STAT6. IRF-1 interacts physically with NF- $\kappa$ B, binds to the distal  $\kappa$ B-binding site of the iNOS promoter region, and stimulates transcription. Only when NF- $\kappa$ B is absent, IRF-2 can bind to the ISRE site and block transcription. Stimulatory pathways are indicated by green arrows (→), and inhibitory pathways are drawn in red (Ellermann-Eriksen Virology Journal 2005).



## Regulation of iNOS induction at the cellular level

Cytokines controlling the iNOS induction in macrophages during early HSV infection. IFN- $\gamma$ , produced mainly by NK cells, stimulates iNOS production. This IFN- $\gamma$ -induced production of iNOS can be inhibited by IL-4. Upon HSV (herpes simplex virus) infection of macrophages they produce TNF which synergizes with the IFN- $\gamma$ -induced pathways and inhibits the inhibitory signals of IL-4. Thus, the virus overrules the restrictive signals and opens up for an otherwise closed pathway. Stimulatory pathways are indicated by green arrows (→), and inhibitory pathways are drawn in red (Ellermann-Eriksen Virology Journal 2005).


# Toll-like receptory

---

---

- transmembránové proteiny
- bunky, intestinálne epitelové bunky
- 13 členov (niektoré sú transmembránové)
- Rozpoznávajú molekuly patogénov (napríklad fragmenty bakteriálnej DNA)

IFN- $\gamma$ , IL-1, TNF receptory



## Regulácia iNOS sprostredkovaná NF-κB

štrukturálne a evolučne konzervovaná rodina proteínov pozostáva z piatich členov: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB a c-Rel

Transkripčné faktory NF-κB sa v nestimulovaných bunkách nachádzajú v inaktívnej forme (diméry) a nevyznačujú sa žiadnym účinkom na transkripciu príslušných génov

Ich aktivácia je kontrolovaná inhibičnou podjednotkou zo skupiny inhibítorov kappaB (IκB)

K aktivácii NF-κB dochádza pod vplyvom rôznych faktorov:

Nešpecificky ●

Špecificky pomocou ligandov TNF-α, IL-1, CD-40L a LPS → aktivujú transkripčné faktory NF-κB prostredníctvom špecifických receptorov

aktivácia IκB kináz (IKK) (fosforylujú IκB zložku inaktívneho komplexu NFκB-IκB)


Uvoľnením inhibítora sa NF-κB stávajú aktívnymi a sú translokované do jadra

Vazba na svoj responzívny element a spustenie expresie cieľových génov

NF-κB reguluje expresiu génov, ktoré hrajú veľmi dôležitú úlohu v nešpecifickej imunite: cytokíny (IL-1, IL-2, IL-6, IL-12, TNF-α, L $\alpha$ , L $\beta$  a GM-CSF), adhezívne molekuly (ICAM, VCAM),●proteíny akútnej fázy (SAA) a indukibilné enzýmy (iNOS a COX-2). Väzbou NF-κB na DNA dochádza zároveň k spätnej indukcii transkripcie IκB. Inhibítor sa znova viaže na aktívne proteíny NF-κB.

**Aktivácia NF-κB je nevyhnutná pre LPS indukovanú expresiu iNOS, a používaním NF-κB inhibítorov dochádza k blokovaniu iNOS expresie a produkcie oxidu dusnatého v makrofágoch.**





# Regulácia iNOS sprostredkovaná MAP kinázami

ERK (extracelulárnymi signálmi regulované kinázy),

p38 MAPK

JNK (c-Jun amino-terminálne kinázy)

Sprostredkujú fosforyláciu ďalších proteínov (proteín kinázy, fosfolipázy, transkričné faktory a proteíny cytoskeletu)

V bunkách majú rôzne funkcie


ERK regulujú bunkovú proliferáciu a diferenciáciu

p38 MAPK a JNK sprostredkovávajú apoptózu

p38 MAPK a ERK sú zapojené aj do regulácie expresie niektorých prozápalových génov (iNOS, IL-6)

•

•



# Inhibitors of NOS

widely used in experimental research

still in under investigation for clinical application

Treatment with NOS inhibitors (chronic inflammatory diseases, e.g. rheumatoid arthritis)




Some such drugs are derivatives of arginine

alkyl derivatives of isothiourea are very potent inhibitors of NOS

Some experimental inhibitors that indeed do show some preference for iNOS and nNOS

selective inhibition of iNOS should be advantageous in septic shock and in chronic inflammatory diseases





# Detekce NO

## Priame stanovenie NO:

Gas-phase chemiluminescence assay

Electron paramagnetic resonance (EPR)

Electrochemical detection

cell-permeabilní fluorescenční indikátory (4,5-diaminofluorescein diacetate (DAF-2 DA))

# Gas-phase chemiluminescence assay


## NO Detection by Gas Phase Chemiluminescence

### Detection Principle:

NO is purged from an aqueous solution using an inert gas such as Ar or He and transferred to a mixing chamber where it reacts with O<sub>3</sub> under reduced pressure.




The light emitted by excited NO<sub>2</sub> upon returning to the ground state is measured by photon counting (*fmol-pmol*). Not very useful when attempting to quantify NO in physiological fluids such as serum, plasma or urine. Why?



# cell-permeabilní fluorescenční indikátory (4,5-diaminofluorescein diacetate (DAF-2 DA))

## Bioimaging of Nitric Oxide Using Diaminofluoresceine-2 (DAF-2)



**Advantages:** Sensitivity for NO (5 nM in vitro) with high temporal and spatial resolution.



No cross-reactivity to  $\text{NO}_2^-/\text{NO}_3^-$  and ONOO $^-$

*Kojima et al., Biol.Pharm. Bull. (1997)*

**Assay limitations:** Possible interference by reducing agents and divalent cations, requires standardized illumination conditions



# Electrochemical detection



# Nepriame stanovenie NO:

celková koncentrace nitrátů/nitritů (Griessova metoda)

aplikace NO donorů compounds, NO scavengerů, a guanylyl-cyklázy



NOS aktivita v buněčných homogenátech měřením enzymatické konverze argininu na citrulin během tvorby NO

inhibitory NOS (L-NAME)

aplikace protilátek k isoformám NOS (imunocytochemie, immunoblotting)

exprese genu pro iNOS





Parkinson's Disease

Cardiovascular Disease

Impotence (Viagra®)

